Skip to search formSkip to main contentSkip to account menu

KW 2449

Known as: FLT3/ABL/Aurora Kinase Inhibitor KW-2449, KW-2449, KW2449 
An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
KCC2 expression–enhancing small molecules rescue cellular and behavior deficits in human RTT neurons and Mecp2 mutant mice… 
Highly Cited
2011
Highly Cited
2011
We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor… 
Highly Cited
2011
Highly Cited
2011
Purpose: The purpose of this study was to determine whether histone deacetylase (HDAC) inhibitors (HDACI) such as vorinostat or… 
Highly Cited
2010
Highly Cited
2010
We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and… 
Highly Cited
2009
Highly Cited
2009
Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute myeloid leukemia (AML) and confer a poor… 
Highly Cited
2009
Highly Cited
2009
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients… 
Review
2009
Review
2009
Imatinib is considered standard therapy for patients with chronic myelogenous leukemia (CML), inducing a high rate of hematologic… 
2008
2008
Background: Activating mutations of FMS-like tyrosine kinase 3 (FLT3) occur in 30% of patients with de novo AML and confer a poor… 
2007
2007
Constitutive activation of FLT3 kinase is associated with poor prognosis in AML and is present in 30–40% of AML patients. KW-2449…